8-KLeadership ChangesExhibits & Filings

PFIZER INC 8-K Report, Executive Changes (Feb 27, 2007)

Filed February 27, 2007For Securities:PFE

Summary

This Form 8-K filing from Pfizer Inc. (PFE), dated February 27, 2007, announces significant changes in its Board of Directors and executive team. Notably, Ruth J. Simmons will not seek re-election to the Board at the upcoming annual meeting due to increased responsibilities at Brown University, though she will remain a director until then. The filing also details the departure of Karen Katen, Vice Chairman and President of Pfizer Human Health, effective March 31, 2007. Ms. Katen's departure agreement includes a severance payment of approximately $5.5 million and outplacement services, contingent on her adherence to confidentiality and non-competition covenants. Furthermore, the report outlines amendments to the Change-in-Control Severance Agreements for several key officers, including Jeffrey B. Kindler and Ian C. Read. These amendments modify the calculation of severance pay in the event of termination without cause or resignation for good reason following a change in control. Specifically, for Messrs. Levin and Read, provisions regarding performance-contingent share awards were adjusted from a maximum to a target basis in such scenarios. These changes are important for understanding executive compensation and potential payouts during corporate transitions.

Key Highlights

  • 1Ruth J. Simmons to not stand for re-election to the Board of Directors at the April 26, 2007 annual meeting, citing increased responsibilities as President of Brown University.
  • 2Karen Katen, Vice Chairman and President – Pfizer Human Health, will depart the company effective March 31, 2007.
  • 3Ms. Katen's departure agreement includes a severance payment of approximately $5.5 million and up to $100,000 in outplacement services.
  • 4Ms. Katen's agreement includes customary confidentiality and non-competition covenants, litigation assistance, and a release of claims.
  • 5Amendments to Change-in-Control Severance Agreements for key officers (Kindler, LaMattina, Levin, Read, Shedlarz) were made effective February 22, 2007.
  • 6The amendment changes the severance amount calculation in a change-in-control scenario to 2.99 times the greater of annual salary plus prior year's incentive or current year's target incentive.
  • 7For Messrs. Levin and Read, performance-contingent share awards in a change-in-control termination will now be based on the target number of shares, not the maximum, under amended agreements.

Frequently Asked Questions

The primary direct financial impact disclosed is the severance payment of approximately $5.5 million and up to $100,000 in outplacement services to Karen Katen. The agreement also requires her to adhere to confidentiality and non-competition clauses, which helps protect Pfizer's business interests.

The amendments to the Change-in-Control Severance Agreements appear to refine the calculation of severance pay and the treatment of performance-contingent share awards in specific scenarios following a change in control. This may be to align with current compensation practices, manage potential liabilities, or adjust the incentives for executives during potential corporate transactions.

While not explicitly defined in this filing, 'Change in Control' typically refers to a significant event such as a merger, acquisition, or takeover of the company. 'Termination for Good Reason' generally means an executive resigns due to specific material adverse changes in their role or compensation, as defined in the agreement, following a Change in Control. These provisions are designed to protect executives in situations where their employment status is significantly altered by a change in company ownership or control.

This filing details one executive departure (Karen Katen) and one director not seeking re-election (Ruth J. Simmons). While any departure is noteworthy, the filing does not indicate a broader trend of executive turnover. The amendments to severance agreements are standard practice and may not signal immediate planned departures.